Universität zu Köln

Al-Batran, S-E, Guentner, M., Pauligk, C., Scholz, M., Chen, R., Beiss, B., Stopatschinskaja, S., Lerbs, W., Harbeck, N. and Jaeger, E. (2010). Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials. Br. J. Cancer, 103 (10). S. 1518 - 1524. LONDON: NATURE PUBLISHING GROUP. ISSN 1532-1827

Full text not available from this repository.

Abstract

BACKGROUND: The aim of this study was to determine the activity of anthracycline rechallenge using pegylated liposomal doxorubicin (PLD) in patients with metastatic breast cancer (MBC) previously treated with conventional anthracyclines. METHODS: Pooled individual data from four prospective trials were used, and the primary end point of the pooled analysis was clinical benefit rate (CBR). The studies comprised 935 patients, of whom 274 had received PLD in the metastatic setting after prior exposure to conventional anthracyclines (rechallenge population). RESULTS: The majority of patients were heavily pretreated. Previous anthracycline therapy was administered in the adjuvant (14%) or metastatic setting (46%), or both (40%). The overall CBR from rechallenge with PLD was 37.2% (95% CI, 32.4-42.0). In univariate analyses, the CBR was significantly higher in patients with less exposure to prior chemotherapy, in taxane-naive patients, and in patients with a favourable Eastern Cooperative Group performance status of 0 vs 1 vs 2 (53.3 vs 35.5 vs 18.2%; P<0.001). In multivariate analyses, performance status proved to be the only independent predictor of the CBR achieved with PLD rechallenge (P=0.038). There was no statistically significant difference in CBR regarding the setting, cumulative dose of and/or resistance to prior anthracyclines, or time since prior anthracycline administration. CONCLUSION: Anthracycline rechallenge using PLD is effective in patients with MBC who have a favourable performance status, regardless of setting, resistance, cumulative dose or time since prior conventional anthracycline therapy. British Journal of Cancer (2010) 103, 1518-1523. doi:10.1038/sj.bjc.6605961 www.bjcancer.com Published online 26 October 2010 (C) 2010 Cancer Research UK

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Al-Batran, S-E UNSPECIFIED UNSPECIFIED UNSPECIFIED Guentner, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Pauligk, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Scholz, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Chen, R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Beiss, B. UNSPECIFIED UNSPECIFIED UNSPECIFIED Stopatschinskaja, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Lerbs, W. UNSPECIFIED UNSPECIFIED UNSPECIFIED Harbeck, N. UNSPECIFIED UNSPECIFIED UNSPECIFIED Jaeger, E. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-492594
DOI:	10.1038/sj.bjc.6605961
Journal or Publication Title:	Br. J. Cancer
Volume:	103
Number:	10
Page Range:	S. 1518 - 1524
Date:	2010
Publisher:	NATURE PUBLISHING GROUP
Place of Publication:	LONDON
ISSN:	1532-1827
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language MULTICENTER PHASE-II; 1ST-LINE TREATMENT; PREDICTIVE FACTORS; LINE CHEMOTHERAPY; CLINICAL BENEFIT; CAPECITABINE; DOCETAXEL; CARDIOTOXICITY; GEMCITABINE; COMBINATION Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/49259